Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Vancouver will begin offering pharmaceutical-grade pills to opioid drug users in the latest attempt to prevent deaths in a city that experiences one lethal overdose every day.

A pilot project set to launch from Vancouver’s largest social-service provider will allow about 50 patients at a time to access the opioid hydromorphone in tablet form and ingest them on site while staff observe them. This offers a safer alternative to an illicit drug supply tainted by deadly fentanyl.

At least 1,380 people died of illicit drug overdoses in British Columbia from January to November of this year, with fentanyl detected in about 84 per cent of deaths.

Story continues below advertisement

The PHS Community Services Society program, to launch Jan. 8 at the Molson Overdose Prevention Site in Vancouver’s Downtown Eastside, is an expansion of an injectable opioid program available on a relatively small scale at four PHS sites and at the Crosstown Clinic in Vancouver. (Surrey also has an injectable hydromorphone program.)

A separate program also expected to roll out early in the new year intended to provide more open access to opioid drug users will allow people to take hydromorphone pills with them.

Hydromorphone is an opioid medication used to treat moderate to severe pain that is commonly used in palliative and acute care. One Vancouver study found people who use heroin could not differentiate between the two, suggesting hydromorphone could be an affordable and effective substitution therapy.

PHS medical director Christy Sutherland said the idea to dispense the drug in pill form came from patients themselves, who were not satisfied with the injectable program.

“When I chat with them about it, they will say they don’t think it’s as effective as the tablets – that when they were using tablets on the street, they actually felt better,” Dr. Sutherland said.

“And so for patients who have been unable to stabilize on the traditional injectable program with the liquid hydromorphone, we thought we needed another option with them.”

Dr. Christy Sutherland at the Portland Hotel Society Health Clinic, Aug. 28, 2018.

Rob Newell

Since September, 2016, Dr. Sutherland has started more than 300 people on injectable hydromorphone. It operates at three PHS housing sites and at the Molson OPS, and there are 50 to 60 people on it at one time.

Story continues below advertisement

Meanwhile, the Crosstown Clinic – the only one in North America to offer prescription diacetylmorphine (heroin) – has roughly 100 patients at any given time on either heroin or injectable hydromorphone. As of this week, there are 104 patients on diacetylmorphine and 16 on hydromorphone.

“It’s so nice to be able to provide people with choices for when they’re deciding what they need for treatment for their opiate-use disorder,” Dr. Sutherland said. Methadone was the only available option not too long ago, she added, and while it is effective for many people with opioid-use disorder, it is not right for everyone.

Also expected in the new year is the rollout of a hydromorphone pilot project led by Mark Tyndall, executive director of the BC Centre for Disease Control (BCCDC). Unlike the PHS program, which requires ingestion to be witnessed by staff, this program will dispense pills for drug users to take with them.

Dr. Tyndall describes the BCCDC project as having a less restrictive, less medicalized approach that will hopefully appeal to those who will not use their drugs in a clinical setting.

“We’re supposed to be meeting people where they’re at, and we’re actually meeting regulators where they’re at,” he said. “We’re trying to work within a structure that’s just not flexible enough to allow people access to these drugs.”

Dr. Tyndall is still in the process of securing ATM-style machines – with biometric scanners, real-time monitoring and alarm systems – that would distribute the pills to patients. The goal is to roll out the program with staff distributing the pills early in the new year and then transitioning to machine distribution a few months later.

Story continues below advertisement

Vancouver Mayor Kennedy Stewart’s overdose emergency task force this month issued its first recommendations on the overdose crisis, which included securing a storefront space for the BCCDC project by April, 2019, at the latest.

Dr. Tyndall has said before that his low-barrier initiative is not a clinical response, but a public-health response amid an unprecedented crisis. An illicit supply supplanted by the powerful opioid fentanyl has caused overdose deaths to surge across North America over the past five years.

Injectable therapy requires a patient to visit a clinic two or three times a day to inject under supervision, does not allow for take-home doses and can cost up to $25,000 a person every year.

In comparison, an eight-milligram hydromorphone pill costs 32 cents – or $700 for two pills, three times a day for a year.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies